Nicholas Adams Joins OxSonics as Chief Business Officer
Nicholas Adams Joins OxSonics as Chief Business Officer
Oxford, UK – 5th August 2020 – OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced that Mr. Nicholas Adams has joined the company as Chief Business Officer.
Nicholas brings over 30years experience in the pharmaceutical and biotech industries and for the past 16 years has led entire Business Development functions at, and been on the Executive Teams of, Antisoma, Clavis Pharma, Redx Pharma and most recently ReNeuron. Over this time Nicholas has led or been instrumental in over 25 global deals (including in-and out-licensing, divestments, spin-outs, royalty buy-out and M&A) where the out-licensing and divestment deals generated over US$240m.
Nicholas will lead the Business Development function and drive clinician engagement for the company.
Colin Story, CEO, commented: “I’m delighted to welcome Nick to the executive team as Chief Business Officer. Nick not only brings a wealth of experience both from his earlier career in oncology clinical development but also an enviable track record of consistent high value deal making across many years in commercial roles. As we transition to a clinical stage company Nick is ideally placed to drive our partnering programmes and clinician engagement activities forward.”
Nicholas Adams, CBO, commented: “I’ve followed OxSonics impressive progress over the past 18 months and I’m delighted to join as it transitions into being a clinical stage company. I look forward to forming partnerships with Pharma companies and building a network of clinical collaborators.”
– ENDS –
About OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.
The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.
The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.
OxSonics is based in Oxford in the UK.
For more information please visit: www.oxsonics.com.